Compare ADMA Biologics Inc (ADMA) vs Duke Energy Corp (DUK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Duke Energy Corp — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Duke Energy Corp trades at $126.86 (market cap $99.96B). The key difference: Duke Energy Corp is far larger — about 46.9× ADMA Biologics Inc's market cap, and Duke Energy Corp pays a 3.32% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | DUK | |
|---|---|---|
Market Cap | $2.13B | $99.96B |
Sector | Health | Utilities |
52-Week High | $20.38 | $133.46 |
52-Week Low | $7.60 | $113.99 |
Enterprise Value | $2.20B | $190.00B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Duke Energy (DUK) trades at $128.22, down 1.06% on the day, with a bullish technical signal supported by moving averages. The company shows steady revenue growth, reaching $32.24B in 2025, and has beaten earnings estimates for the last three quarters. A $1.07 dividend is scheduled for June 2026. Analyst consensus is a Buy with a $137.67 price target, though the stock faces headwinds from high debt levels and regulatory pressures.
DUK presents a stable investment with consistent earnings and a solid dividend, but investors should weigh the upside from infrastructure investments against rising debt and regulatory risks. The stock's current valuation is reasonable, with potential for moderate growth if execution on its $103B capital plan remains on track.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →
